Healthcare Policy and Diagnostic Advancements: Insights from Dr. Bruce Quinn
- Special guest: Dr. Bruce Quinn, an expert in diagnostics and healthcare policy.
- Topics: Diagnostic advancements, AI in healthcare, precision medicine, and healthcare policy.
Episode Highlights:
West Coast Update:
- Dr. Quinn shares a weather update and personal reflections from the West Coast.
AI and Precision Medicine:
- Discussion on the embryonic stage of AI and precision medicine integration.
- Specific applications of AI in diagnostics, including grading cancer and recording patient visits.
- Dr. Quinn’s personal experience using AI tools like ChatGPT for medical inquiries.
Investment Trends in Diagnostics:
- Surge in diagnostic investments driven by AI and precision medicine.
- Example: Sophia Genetics’ recent performance.
- Impact of COVID-19 on biotech investments, with companies like Invitae experiencing dramatic valuation changes.
- Challenges in the fundraising environment for new diagnostic ventures post-COVID bubble.
Consumer Diagnostics:
- Exploration of retail diagnostics and at-home testing.
- Challenges in advancing point-of-care testing and its unmet needs.
- Potential for integration with consumer health platforms like Hims & Hers and Roman.
Genomics and Financial Landscape:
- Overview of recent acquisitions, like LabCorp acquiring Invitae.
- The fluctuating valuations and investor confidence in the genomics sector.
CMS and Healthcare Policy:
- Dr. Quinn discusses the CMS Moldex program focused on genomics and its impact on diagnostics.
- Innovations in Medicare to support chronic disease management and dementia care.
- Regulatory changes and the future of lab-developed tests (LDTs).
Prostate Cancer Diagnostics:
- Advances in diagnostic tests for prostate cancer and their clinical implications.
- Importance of precision diagnostics in treatment decisions.
Neuro-Diagnostics and Alzheimer's:
- Emerging blood tests for Alzheimer's disease and their integration into clinical practice.
- Genetic testing and its role in diagnosing and managing Alzheimer’s disease.
Regulatory Landscape and Elections:
- Impact of upcoming elections on healthcare policy and CMS innovation.
- FDA’s proposed regulations on lab-developed tests and potential industry shifts.
Closing Thoughts:
- Predictions on future investment opportunities in diagnostics.
- Areas of growth: precision diagnostics, AI applications, and molecular pathways in diagnostics.
Creators and Guests
Host
Rick Gannotta
Health sector executive clinician educator & researcher, RTs/links 🚫 not endorsements, TEDX; https://t.co/51mnBxpPqv @NYUWagner